Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction

Mary Frances McMullin, Claire N. Harrison

Blood blood.2023022418.

https://doi.org/10.1182/blood.2023022418

Published: 2024

Journal Articles

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

Blood (2023) 142 (Supplement 1): 702.

https://doi.org/10.1182/blood-2023-180720

Published: 2023

Journal Articles

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, Marta Sobas, Parvis Sadjadian, Natalia Curto-Garcia, Lee-Yung Shih, Timothy Devos, Dorota Krochmalczyk, Serena Galli, Maria Bieniaszewska, Ilona Seferynska, Mary Frances McMullin, Anna Armatys, Adrianna Spalek, Joanna Waclaw, Mihnea Tudor Zdrenghea, Laurence Legros, Francois Girodon, Krzysztof Lewandowski, Anna Angona Figueras, Jan Samuelsson, Aitor Abuin Blanco, Pascale Cony-Makhoul, Angela Collins, Chloe James, Rajko Kusec, Marie Lauermannova, Maria Soledad Noya, Malgorzata Skowronek, Lukasz Szukalski, Anna Szmigielska-Kaplon, Marielle Wondergem, Iryna Dudchenko, Joanna Gora-Tybor, Kamel Laribi, Anna Kulikowska De Nalecz, Jean-Loup Demory, Katell Le Du, Sonja Zweegman, Carlos Besses Raebel, Radek C. Skoda, Stephane Giraudier, Martin Griesshammer, Jean-Jacques Kiladjian, Claire N Harrison

Blood (2023) 142 (Supplement 1): 748.

https://doi.org/10.1182/blood-2023-185108

Published: 2023

Journal Articles

The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups

Jennifer O Sullivan, Amy Wood, Sean Wen, Angela Hamblin, Sonia Fox, Christina Yap, Mary Frances McMullin, Nicholas C. P. Cross, Claire N Harrison, Adam J Mead

Blood (2023) 142 (Supplement 1): 4552.

https://doi.org/10.1182/blood-2023-185043

Published: 2023

Journal Articles

Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib

Stephen T. Oh, Jamile Shammo, Vikas Gupta, Mary Frances McMullin, Prithviraj Bose, Ruben A. Mesa, Alessandro Lucchesi, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John Mascarenhas, Francisca Ferrer Marin

Blood (2023) 142 (Supplement 1): 4566.

https://doi.org/10.1182/blood-2023-178753

Published: 2023

Journal Articles

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Blood (2022) 140 (Supplement 1): 821–823.

https://doi.org/10.1182/blood-2022-160409

Published: 2022

Journal Articles

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Blood (2022) 140 (Supplement 1): 2002–2004.

https://doi.org/10.1182/blood-2022-159503

Published: 2022

Journal Articles

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Blood (2022) 140 (Supplement 1): 9677–9680.

https://doi.org/10.1182/blood-2022-162547

Published: 2022

Journal Articles

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Francesco Passamonti, James M. Foran, Anand Tandra, Valerio De Stefano, Maria Laura Fox, Ahmad H. Mattour, Mary Frances McMullin, Andrew Charles Perkins, Gabriela Rodríguez-Macias, Hassan Sibai, Qin Qin, Yan Sun, Jalaja Potluri, Jason Harb, Jonathan How

Blood (2022) 140 (Supplement 1): 583–585.

https://doi.org/10.1182/blood-2022-157949

Published: 2022

Journal Articles

UBASH3B knockout Downregulates STAT1 Mediated Interferon Signalling and Megakaryocyte Related Genes in a JAK2 V617F Positive MPN Model

Graeme M Greenfield, Deirdra Venney, Jaine Blayney, Mary Frances McMullin, Ken I Mills

Blood (2022) 140 (Supplement 1): 6752–6754.

https://doi.org/10.1182/blood-2022-167709

Published: 2022

Journal Articles

Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

Blood (2022) 140 (Supplement 1): 2654–2655.

https://doi.org/10.1182/blood-2022-167119

Published: 2022

Journal Articles

Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Blood (2022) 140 (Supplement 1): 1781–1783.

https://doi.org/10.1182/blood-2022-157273

Published: 2022

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Francis J. Mussai, Ian Thomas, Cono Ariti, Laura Upton, Mia Sydenham, Alan K. Burnett, Steve Knapper, Priyanka Mehta, Mary Frances McMullin, Mhairi Copland, Nigel H. Russell, Robert Hills

Blood (2021) 138 (Supplement 1): 2355.

https://doi.org/10.1182/blood-2021-148323

Published: 2021

Journal Articles

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Chandan Saha, Carolyn Mead-Harvey, Adam J. Mead, Rebecca H. Boucher, Sonia Fox, Isaak Ailts, Christina Yap, Aimee E Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Ruben A. Mesa, Robyn Scherber, Mary Frances McMullin, Holly L. Geyer, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2021-151568

Published: 2021

Journal Articles

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

Blood (2021) 138 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2021-146061

Published: 2021

Journal Articles

Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

Isaak Ailts, Carolyn Mead-Harvey, Adam J. Mead, Sonia Fox, Rebecca H. Boucher, Christina Yap, Chandan Saha, Robyn Scherber, Aimee Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Mary Frances McMullin, Ruben A. Mesa, Claire N. Harrison, Holly L. Geyer

Blood (2021) 138 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2021-147637

Published: 2021

Journal Articles

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Claire Harrison, DM, FRCP, FRCPath, Joanna Baxter, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Thomas McKerrell, MD PhD, Aimee Jackson, BSc, MSc, Rachel S Fletcher, PhD, Adam J. Mead, MD PhD, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Joanne Ewing, MD PhD, Nauman M Butt, MD, Manish Jain, MBBS, MRCP, FRCpath, Sebastian Francis, MBChB, FRCPath, MD, Fiona J Clark, FRCP, FRCPath, Jason Coppell, MBBS, Mary Frances McMullin, MDFRCP, FRCPath, Frances Wadelin, MB ChB, PhD FRCPath, Srinivasan Narayanan, FRCP, FRCPath, Dragana Milojkovic, Mark W. Drummond, PhD FRCPath, Mallika Sekhar, MBBS, MD, Maike Paramor, James Roberts, BSc, Rachel Glover, BSc, Erica Harris, MSc, Luigi Grassi, PhD, Alba Rodriguez-Meira, PhD, Jason Carroll, PhD FMedSci, José-Ezequiel Martín, PhD, Giuditta Corbizi Fattori, PhD, Zijian Fang, BSc, Anna L Godfrey, BMBCh, PhD, Simón Méndez-Ferrer, PhD

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-134764

Published: 2020

Journal Articles

Ruxolitinib: gaining more than intended

Graeme Greenfield, Mary Frances McMullin

Blood (2020) 135 (13): 983–984.

https://doi.org/10.1182/blood.2020005135

Published: 2020

Journal Articles

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study

Blood (2020) 135 (5): 381–386.

https://doi.org/10.1182/blood.2019002614

Published: 2020

Includes: Supplemental data

NARROW

How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups

Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

UBASH3B knockout Downregulates STAT1 Mediated Interferon Signalling and Megakaryocyte Related Genes in a JAK2 V617F Positive MPN Model

Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Ruxolitinib: gaining more than intended

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only